Seeking Alpha

BofA weighs in on Amgen (AMGN +1.1%) after digesting recent events related to the firm including...

BofA weighs in on Amgen (AMGN +1.1%) after digesting recent events related to the firm including its planned buyback of $5B worth of stock. Analysts cite prescription sales trends and a favorable dollar/euro climate as drivers, as they slot in 2012 EPS at $6.13 vs. the Street's $5.82.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)